Bayer's Asundexian Cuts Recurrent Stroke Risk by 26% Without Added Bleeding, Wins China Approval as FDA Review Advances
· techtimes.com · popularity 20/100 · 0 similar stories today
Read the original at techtimes.com →
Summary
Bayer's asundexian reduces recurrent stroke risk 26% without added bleeding in OCEANIC-STROKE. Approved in China (Sunharbo®); under FDA Priority Review. AHA 2026 coverage.
Found in: Tech Times. Rating basis: single outlet; outlet tier 2 (unlisted); 1 feeds; feed position 5.